Effect of m-Chlorophenylpiperazine on plasma homovanillic acid concentrations in healthy subjects

RenéS S. Kahn, Peter Knott, Steven Gabriel, Kimberly DuMont, Lisa Mastroianni, Michael Davidson

Research output: Contribution to journalArticlepeer-review

Abstract

In view of the abundant anatomical and functional interactions between serotonin and dopamine systems, this study examined the effect of the serotonin agonist, m-chlorophenylpiperazine (mCPP) on plasma concentrations of the dopamine metabolite, homovanillic acid. Plasma prolactin levels, body temperature, and mCPP blood level were also measured. mCPP (0.35 mg/kg) and placebo were administered orally to 10 healthy men in a randomized double-blind design. Variables were measured for 210 min after administration of capsules. mCPP raised prolactin and temperature as compared to placebo, but did not affect plasma homovanillic acid concentrations. Results suggest that mCPP does not alter dopamine function.

Original languageEnglish
Pages (from-to)1055-1061
Number of pages7
JournalBiological Psychiatry
Volume32
Issue number11
DOIs
StatePublished - 1 Dec 1992
Externally publishedYes

Fingerprint

Dive into the research topics of 'Effect of m-Chlorophenylpiperazine on plasma homovanillic acid concentrations in healthy subjects'. Together they form a unique fingerprint.

Cite this